Antifungal susceptibility testing of Aspergillus species complex in the Clinical Laboratory: how to do it, when to do it, and how to interpret it


Submitted: 11 December 2014
Accepted: 11 December 2014
Published: 11 December 2014
Abstract Views: 2578
PDF: 1002
HTML: 1216
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Esther Manso Comitato di Studio per la Micologia (CoSM), Associazione Microbiologi Clinici Italiani, Milano; Laboratorio di Analisi Chimico-cliniche e Microbiologia, Azienda Ospedaliera-Universitaria Ospedali Riuniti di Ancona, Italy.
  • Claudio Farina Comitato di Studio per la Micologia (CoSM), Associazione Microbiologi Clinici Italiani, Milano; USC Microbiologia e Virologia, Azienda Ospedaliera “Papa Giovanni XXIII”, Bergamo, Italy.
  • Stefano Andreoni Comitato di Studio per la Micologia (CoSM), Associazione Microbiologi Clinici Italiani, Milano; Laboratorio di Microbiologia e Virologia, Azienda Ospedaliero-Universitaria “Maggiore della Carità di Novara”, Italy.
  • Elisabetta Blasi Comitato di Studio per la Micologia (CoSM), Associazione Microbiologi Clinici Italiani, Milano; Dipartimento di Medicina Diagnostica, Clinica e Sanità Pubblica, Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
  • Marco Conte Comitato di Studio per la Micologia (CoSM), Associazione Microbiologi Clinici Italiani, Milano; Laboratorio di Microbiologia e Virologia, Azienda Ospedaliera Specialistica dei Colli “Monaldi-Cotugno-CTO”, Napoli, Italy.
  • Paolo Fazii Comitato di Studio per la Micologia (CoSM), Associazione Microbiologi Clinici Italiani, Milano; Laboratorio di Microbiologia e Virologia, Ospedale Civile “Santo Spirito”, Pescara, Italy.
  • Gianluigi Lombardi Comitato di Studio per la Micologia (CoSM), Associazione Microbiologi Clinici Italiani, Milano; Laboratorio di Analisi Chimico-cliniche e Microbiologia, Azienda Ospedaliera “Niguarda – Ca’ Granda”, Milano, Italy.
  • Silvana Sanna Comitato di Studio per la Micologia (CoSM), Associazione Microbiologi Clinici Italiani, Milano; Servizio di Microbiologia Clinica, Azienda Ospedaliero-Universitaria “Sassari”, Italy.

The emergence of drug resistance in fungal pathogens has a profound impact on human health given limited number of antifungal drugs. Antifungal resistance in Aspergillus spp. infection can be encountered in the antifungal drug-exposed patient due to selection of intrinsically resistant species or isolates with acquired resistance belonging to species that are normally susceptible. Resistance to triazoles is not common in Aspergillus spp., however, triazole resistance in A. fumigatus appears to be increasing in several European countries in recent years and can be clinically relevant. The Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing have developed breakpoints and epidemiological cutoff values that are now established for Aspergillus spp. Clinical microbiology laboratories will be employed commercial susceptibility assays, rather than reference broth microdilution methods and comparative studies are particularly important.


Manso, E., Farina, C., Andreoni, S., Blasi, E., Conte, M., Fazii, P., Lombardi, G., & Sanna, S. (2014). Antifungal susceptibility testing of Aspergillus species complex in the Clinical Laboratory: how to do it, when to do it, and how to interpret it. Microbiologia Medica, 29(2). https://doi.org/10.4081/mm.2014.4889

Downloads

Download data is not yet available.

Citations


Similar Articles

You may also start an advanced similarity search for this article.